Optimization of sup 125 I ophthalmic plaque brachytherapy
- Univ. of Southern California School of Medicine, Los Angeles (USA)
Episcleral plaques containing {sup 125}I sources are often used in the treatment of ocular melanoma. Within four years post-treatment, however, the majority of patients experience some visual loss due to radiation retinopathy. The high incidence of late complications suggests that careful treatment optimization may lead to improved outcome. The goal of optimization would be to reduce the magnitude of vision-limiting complications without compromising tumor control. We have developed a three-dimensional computer model for ophthalmic plaque therapy which permits us to explore the potential of various optimization strategies. One simple strategy which shows promise is to maximize the ratio of dose to the tumor apex (T) compared to dose to the macula (M). By modifying the parameters of source location, activity distribution, source orientation, and shielding we find that the calculated T:M ratio can be varied by a factor of 2 for a common plaque design and posterior tumor location. Margins and dose to the tumor volume remain essentially unchanged.
- OSTI ID:
- 5892752
- Journal Information:
- Medical Physics; (USA), Vol. 17:6; ISSN 0094-2405
- Country of Publication:
- United States
- Language:
- English
Similar Records
Dosimetric Benefit of a New Ophthalmic Radiation Plaque
Radiation complications and tumor control after {sup 125}I plaque brachytherapy for ocular melanoma
Related Subjects
EYES
MELANOMAS
RADIOTHERAPY
OPTIMIZATION
COMPUTERIZED SIMULATION
IODINE 125
PLANNING
RADIATION DOSES
BETA DECAY RADIOISOTOPES
BODY
BODY AREAS
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
FACE
HEAD
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANS
RADIOISOTOPES
RADIOLOGY
SENSE ORGANS
SIMULATION
THERAPY
550603* - Medicine- External Radiation in Therapy- (1980-)